A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
==== Weight loss ==== Prior to the MERIT study, numerous meta-analyses of studies on ESG report a total body weight loss of approximately 16% at one year. Excess weight loss was observed to be approximately 60% at one year. Weight loss reported from high volume community practices that have both expertise in ESG and robust longitudinal aftercare programs with dietitians have shown even greater outcomes, with total body weight loss approaching 30% and excess weight loss of 66% at one year.
Myelinoclastic or demyelinating disorders: Typical forms of multiple sclerosis Neuromyelitis optica, or Devic's disease Idiopathic inflammatory demyelinating diseases Leukodystrophic or dysmyelinating disorders: CNS neuropathies such as those produced by vitamin B12 deficiency Central pontine myelinolysis Myelopathies such as tabes dorsalis (syphilitic myelopathy) Leukoencephalopathies such as progressive multifocal leukoencephalopathy Leukodystrophies The myelinoclastic disorders are typically associated with symptoms such as optic neuritis and transverse myelitis, because the demyelinating inflammation can affect the optic nerve or spinal cord. Many are idiopathic. Both myelinoclastic and leukodystrophic modes of disease may result in lesional demyelinations of the central nervous system.
Robin Harper, a former leader of the Scottish Greens, joins Scottish Labour, citing his former party's failure on the environment for his decision. 12 June – MSPs vote for the early release of 500 prisoners in order to ease overcrowding in the Scottish Prison Service. Edinburgh City Council approves plans by AEG to build an 8,500 capacity stadium at Edinburgh Park. 13 June – Stagecoach Group announces plaans to cut services in north Scotland as it launches a review of its operations. 14 June – Five Scotland fans are taken to hospital after their hire car crashed as they left an airport in Germany driving on the wrong side of the road. The Independent Parliamentary Standards Authority clears Douglas Ross of misusing his travel expenses following an investigation. The 2024 Birthday Honours are published. Among Scots to be recognised are former Prime Minister Gordon Brown, who becomes a Companion of Honour, and footballers Graeme Souness (CBE) and Ally McCoist (MBE). 16 June – Aberdeen City Council cancels the 2024 Highland Games shortly before it is due to commence following "heavier than forecast" rain. 17 June – NHS Dumfries and Galloway warns residents living in the area to assume some of their data has been published online after its database was hacked. 18 June – Scottish Labour launches its general election manifesto. 19 June – The Scottish National Party launches its election manifesto, with plans to "end Westminster cuts" and increase investment in the NHS.
Sources: en.wikipedia.org
=== High Point Media === After Phillips sold his majority interest in EAS, he concentrated on his writing and on promotion of his books through his publishing company, High Point Media, as well as Value Creation, a branch of EAS. Body for Life hit bookstores in 1999, and by 2003 it had sold 3.5 million copies in 24 languages. The book topped the charts in 11 different countries-including the United States, England, Japan, Australia, Greece and Finland. In 2004 USA Today named it among the Top 15 bestselling books of the past decade. In November 2003, Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! was released. In the book Phillips offers his plan "to help inspire and guide even more people to improve their health and lift their quality of life to new heights." In February 2006, Phillips announced his "Great American Transformation Experience" (GATE) with a goal to transform America's fitness from world's worst to first within 10 years. On June 21, 2010, Phillips' latest book, Transformation: The Mindset You Need. The Body You Want. The Life You Deserve was released. A companion website, Transformation.com, that walks individuals through the transformation process was also updated. The site features a community dedicated to supporting its members' personal goals. On July 10, 2010, the book made the New York Times Best Seller list.
1993/3083) Friendly Societies Act 1992 (Transitional and Consequential Provisions) Regulations 1993 (S.I. 1993/3084) Welfare of Animals at Markets (Amendment) Order 1993 (S.I. 1993/3085) Diseases of Animals (Approved Disinfectants) (Amendment) (No. 2) Order 1993 (S.I. 1993/3086) Civil Aviation (Route Charges for Navigation Services) (Second Amendment) Regulations 1993 (S.I. 1993/3098)
In June 1976, scientists from the Scripps Institution of Oceanography obtained the first evidence for submarine hydrothermal vents along the Galápagos Rift, a spur of the East Pacific Rise, on the Pleiades II expedition, using the Deep-Tow seafloor imaging system. In 1977, the first scientific papers on hydrothermal vents were published by scientists from the Scripps Institution of Oceanography; research scientist Peter Lonsdale published photographs taken from deep-towed cameras, and PhD student Kathleen Crane published maps and temperature anomaly data. Transponders were deployed at the site, which was nicknamed "Clam-bake", to enable an expedition to return the following year for direct observations with the DSV Alvin. Chemosynthetic ecosystems surrounding the Galápagos Rift submarine hydrothermal vents were first directly observed in 1977, when a group of marine geologists funded by the National Science Foundation returned to the Clambake sites. The principal investigator for the submersible study was Jack Corliss of Oregon State University. Corliss and Tjeerd van Andel from Stanford University observed and sampled the vents and their ecosystem on February 17, 1977, while diving in the DSV Alvin, a research submersible operated by the Woods Hole Oceanographic Institution (WHOI). Other scientists on the research cruise included Richard (Dick) Von Herzen and Robert Ballard of WHOI, Jack Dymond and Louis Gordon of Oregon State University, John Edmond and Tanya Atwater of the Massachusetts Institute of Technology, Dave Williams of the U.S.
==== Public and listener-supported ==== WKNC-FM – 88.1 FM (College rock), operated by students of North Carolina State University WRKV – 88.9 FM (Contemporary Christian), operated by Educational Media Foundation WCPE-FM – 89.7 FM (Classical) WUNC-FM – 91.5 FM (National Public Radio, North Carolina Public Radio) operated by the University of North Carolina at Chapel Hill WRLY-LP – 93.5 FM (Adult hits), operated by Triangle Access Broadcasting, Inc. WKRP-LP – 101.9 FM (Variety), operated by Oak City Media, Inc.
Sources: en.wikipedia.org
Izonsteride (developmental code name LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme. It was under development by Eli Lilly and Company and Fujisawa for the treatment of benign prostatic hyperplasia but was never marketed. Izonsteride may also be useful in the treatment of androgenic alopecia.
=== Prior experiments === From the earliest days of radio technology, signals had been used for navigation using the radio direction finding (RDF) technique. RDF can determine the bearing to a radio transmitter, and several such measurements can be combined to produce a radio fix, allowing the receiver's position to be calculated. Given some basic changes to the broadcast signal, it was possible for the receiver to determine its location using a single station. The UK pioneered one such service in the form of the Orfordness Beacon. Through the early period of radio development it was widely known that certain materials, especially metal, reflected radio signals. This led to the possibility of determining the location of objects by broadcasting a signal and then using RDF to measure the bearing of any reflections. Such a system saw patents issued to Germany's Christian Hülsmeyer in 1904, and widespread experimentation with the basic concept was carried out from then on. These systems revealed only the bearing to the target, not the range, and due to the low power of radio equipment of that era, they were useful only for short-range detection. This led to their use for iceberg and collision warning in fog or bad weather, where all that was required was the rough bearing of nearby objects. The use of radio detection specifically against aircraft was first considered in the early 1930s. Teams in the UK, US, Japan, Germany and others had all considered this concept and put at least some amount of effort into developing it.
Official site of the federal government Official tourism site Germany from BBC News Germany. The World Factbook. Central Intelligence Agency. Germany from the OECD Germany at the EU Geographic data related to Germany at OpenStreetMap
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.